Metastases-Targeting Radiotherapy and ADT-Reply
JAMA Oncol
.
2023 Nov 1;9(11):1587-1588.
doi: 10.1001/jamaoncol.2023.3631.
Authors
Alexander D Sherry
1
,
Paul G Corn
2
,
Chad Tang
3
4
5
Affiliations
1
Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
2
Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.
3
Department of Genitourinary Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
4
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston.
5
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.
PMID:
37707804
DOI:
10.1001/jamaoncol.2023.3631
No abstract available
MeSH terms
Androgen Antagonists*
Humans
Radiation Oncology*
Radiotherapy
Substances
Androgen Antagonists